Literature DB >> 21948318

Reactive impurities in excipients: profiling, identification and mitigation of drug-excipient incompatibility.

Yongmei Wu1, Jaquan Levons, Ajit S Narang, Krishnaswamy Raghavan, Venkatramana M Rao.   

Abstract

Reactive impurities in pharmaceutical excipients could cause drug product instability, leading to decreased product performance, loss in potency, and/or formation of potentially toxic degradants. The levels of reactive impurities in excipients may vary between lots and vendors. Screening of excipients for these impurities and a thorough understanding of their potential interaction with drug candidates during early formulation development ensure robust drug product development. In this review paper, excipient impurities are categorized into six major classes, including reducing sugars, aldehydes, peroxides, metals, nitrate/nitrite, and organic acids. The sources of generation, the analytical method for detection, the stability of impurities upon storage and processing, and the potential reactions with drug candidates of these impurities are reviewed. Specific examples of drug-excipient impurity interaction from internal research and literature are provided. Mitigation strategies and corrective measures are also discussed.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21948318      PMCID: PMC3225520          DOI: 10.1208/s12249-011-9677-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  61 in total

1.  Influence of peroxide impurities in povidone and crospovidone on the stability of raloxifene hydrochloride in tablets: identification and control of an oxidative degradation product.

Authors:  K J Hartauer; G N Arbuthnot; S W Baertschi; R A Johnson; W D Luke; N G Pearson; E C Rickard; C A Tingle; P K Tsang; R E Wiens
Journal:  Pharm Dev Technol       Date:  2000       Impact factor: 3.133

Review 2.  The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics.

Authors:  Jon O Lundberg; Eddie Weitzberg; Mark T Gladwin
Journal:  Nat Rev Drug Discov       Date:  2008-02       Impact factor: 84.694

3.  Interaction of dextroamphetamine sulfate with spray-dried lactose.

Authors:  S M Blaug; W T Huang
Journal:  J Pharm Sci       Date:  1972-11       Impact factor: 3.534

4.  Antioxidants in pharmaceutical products.

Authors:  M J Akers
Journal:  J Parenter Sci Technol       Date:  1982 Sep-Oct

Review 5.  Inhibitors of endogenous nitrosation. Mechanisms and implications in human cancer prevention.

Authors:  H Bartsch; H Ohshima; B Pignatelli
Journal:  Mutat Res       Date:  1988-12       Impact factor: 2.433

6.  Identification and quantitation of extractables from cellulose acetate butyrate (CAB) and estimation of their in vivo exposure levels.

Authors:  Decheng Ma; Walter R Wasylaschuk; Christopher Beasley; Zhongxi Zack Zhao; Paul A Harmon; John M Ballard; Steven M Pitzenberger; Sandor L Varga; Robert A Reed
Journal:  J Pharm Biomed Anal       Date:  2004-06-29       Impact factor: 3.935

7.  Applications of oxygen polarography to drug stability testing and formulation development: solution-phase oxidation of hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Authors:  M J Kaufman
Journal:  Pharm Res       Date:  1990-03       Impact factor: 4.200

8.  The role of excipients and package components in the photostability of liquid formulations.

Authors:  Robert A Reed; Paul Harmon; Denise Manas; Walter Wasylaschuk; Chris Galli; Ryan Biddell; Paul A Bergquist; William Hunke; Allen C Templeton; Dominic Ip
Journal:  PDA J Pharm Sci Technol       Date:  2003 Sep-Oct

9.  Mechanism of optical isomerization of (S)-N-[1-(2-fluorophenyl)-3,4,6,7- tetrahydro-4-oxopyrrolo[3,2,1-jk] [1,4]-benzodiazepine-3-yl]-1H- indole-2-carboxamide (FK480) in soft capsules containing polyethylene glycol 400 and glycerol.

Authors:  S Fukuyama; N Kihara; K Nakashima; N Morokoshi; S Koda; T Yasuda
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

10.  Understanding drug-excipient compatibility: oxidation of compound A in a solid dosage form.

Authors:  Yongmei Wu; Mandar Dali; Abhishek Gupta; Krishnaswamy Raghavan
Journal:  Pharm Dev Technol       Date:  2009       Impact factor: 3.133

View more
  22 in total

Review 1.  Impact of excipient interactions on solid dosage form stability.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-06-16       Impact factor: 4.200

2.  Stability of benzocaine formulated in commercial oral disintegrating tablet platforms.

Authors:  Melanie Köllmer; Carmen Popescu; Prashanth Manda; Leon Zhou; Richard A Gemeinhart
Journal:  AAPS PharmSciTech       Date:  2013-08-30       Impact factor: 3.246

3.  Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 1: Predicting degradation related impurities and impurity considerations for pharmaceutical dosage forms.

Authors:  Karen M Alsante; Kim Huynh-Ba; Steven W Baertschi; Robert A Reed; Margaret S Landis; Mark H Kleinman; Christopher Foti; Venkatramana M Rao; Paul Meers; Andreas Abend; Daniel W Reynolds; Biren K Joshi
Journal:  AAPS PharmSciTech       Date:  2013-11-27       Impact factor: 3.246

Review 4.  Oxidation of therapeutic proteins and peptides: structural and biological consequences.

Authors:  Riccardo Torosantucci; Christian Schöneich; Wim Jiskoot
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

5.  Minimally invasive method for the point-of-care quantification of lymphatic vessel function.

Authors:  Anna K Polomska; Steven T Proulx; Davide Brambilla; Daniel Fehr; Mathias Bonmarin; Simon Brändli; Mirko Meboldt; Christian Steuer; Tsvetina Vasileva; Nils Reinke; Jean-Christophe Leroux; Michael Detmar
Journal:  JCI Insight       Date:  2019-02-21

6.  Physicochemical interactions in solid dosage forms.

Authors:  Ajit S Narang; Divyakant Desai; Sherif Badawy
Journal:  Pharm Res       Date:  2012-08-31       Impact factor: 4.200

7.  Surface acidity and solid-state compatibility of excipients with an acid-sensitive API: case study of atorvastatin calcium.

Authors:  Ramprakash Govindarajan; Margaret Landis; Bruno Hancock; Larry A Gatlin; Raj Suryanarayanan; Evgenyi Y Shalaev
Journal:  AAPS PharmSciTech       Date:  2014-10-16       Impact factor: 3.246

8.  Mechanism of Decarboxylation of Pyruvic Acid in the Presence of Hydrogen Peroxide.

Authors:  Antonio Lopalco; Gautam Dalwadi; Sida Niu; Richard L Schowen; Justin Douglas; Valentino J Stella
Journal:  J Pharm Sci       Date:  2016-01-29       Impact factor: 3.534

Review 9.  Oxidative Stability in Lipid Formulations: a Review of the Mechanisms, Drivers, and Inhibitors of Oxidation.

Authors:  Jasmine Musakhanian; Jean-David Rodier; Masumi Dave
Journal:  AAPS PharmSciTech       Date:  2022-05-20       Impact factor: 3.246

10.  Fragmentation of a Monoclonal Antibody by Peroxotungstate.

Authors:  Hasitha Rathnayaka; Olivier Mozziconacci; Alavattam Sreedhara; Christian Schöneich
Journal:  Pharm Res       Date:  2018-09-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.